Criteria for facilities and personnel for the administration of parenteral systemic antineoplastic therapy. Adopted on March 3, 2004 by the American Society of Clinical Oncology.
The following American Society of Clinical Oncology (ASCO) position statement represents an update to policy first adopted by the Board in 1997 (J Clin Oncol 15:3416-3417, 1997). The primary change to the statement is the addition of language to section 7, Standards for Antineoplastic Therapy, describing safeguards for preparing and administering chemotherapy drugs. As third-party payors consider and follow through with the establishment of new models for chemotherapy drug procurement, distribution, and delivery, ASCO provides guidance to oncologists to help them ensure the safety and integrity of the drugs they administer. Additionally, section 5, Office Operations, also suggests that oncologists consider measures protecting them from liability associated with drugs obtained from or prepared by outside entities.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D006268:Health Facilities / Q000592:standards*; D006282:Health Personnel; D006801:Humans; D007262:Infusions, Intravenous; D019300:Medical Errors / Q000517:prevention & control; D016134:Organizational Policy; D011361:Professional Competence; D012449:Safety; D012955:Societies, Medical
D000970:Antineoplastic Agents